1,025 reports of this reaction
2.2% of all OXAZEPAM reports
#6 most reported adverse reaction
COMA is the #6 most commonly reported adverse reaction for OXAZEPAM, manufactured by Actavis Pharma, Inc.. There are 1,025 FDA adverse event reports linking OXAZEPAM to COMA. This represents approximately 2.2% of all 46,840 adverse event reports for this drug.
Patients taking OXAZEPAM who experience coma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COMA is a less commonly reported adverse event for OXAZEPAM, but still significant enough to appear in the safety profile.
In addition to coma, the following adverse reactions have been reported for OXAZEPAM:
The following drugs have also been linked to coma in FDA adverse event reports:
COMA has been reported as an adverse event in 1,025 FDA reports for OXAZEPAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
COMA accounts for approximately 2.2% of all adverse event reports for OXAZEPAM, making it a notable side effect.
If you experience coma while taking OXAZEPAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.